Mirae Asset Global ETFs Holdings
CHRS icon

Mirae Asset Global ETFs Holdings’s Coherus Oncology CHRS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.3K Buy
60,186
+9,741
+19% +$15.9K ﹤0.01% 2904
2026
Q1 		$85.3K Buy
50,445
+1,170
+2% +$2.08K ﹤0.01% 2736
2025
Q4 		$70K Sell
49,275
-5
-0% -$7 ﹤0.01% 2829
2025
Q3 		$80.8K Sell
49,280
-14,581
-23% -$16.2K ﹤0.01% 2760
2025
Q2 		$46.7K Sell
63,861
-2,852
-4% -$2.46K ﹤0.01% 2894
2025
Q1 		$53.8K Buy
66,713
+2,839
+4% +$3.27K ﹤0.01% 2837
2024
Q4 		$88.1K Buy
63,874
+4,171
+7% +$4.68K ﹤0.01% 2747
2024
Q3 		$62.1K Buy
59,703
+6,012
+11% +$8.24K ﹤0.01% 2874
2024
Q2 		$92.9K Buy
+53,691
New +$108K ﹤0.01% 2593

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CHRS Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Coherus Oncology (CHRS) stake by 19% in Q2 2026, buying an estimated $15.9K and bringing the position to 60,186 shares worth $84.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Mirae Asset Global ETFs Holdings first reported a position in CHRS in Q2 2024 and has held it in 9 quarters since. The position peaked at $92.9K in Q2 2024. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 60,186 shares of Coherus Oncology worth $84.3K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 9,741 Coherus Oncology shares in Q2 2026, an estimated $15.9K.
  • Coherus Oncology made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2904 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Coherus Oncology in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Coherus Oncology position peaked at $92.9K in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.